aTyr Pharma Inc. (ATYR)
2.78
-0.18 (-6.08%)
At close: Apr 03, 2025, 3:59 PM
2.89
3.99%
After-hours: Apr 03, 2025, 07:55 PM EDT
-6.08% (1D)
| Bid | 2.77 |
| Market Cap | 247.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.86 |
| PE Ratio (ttm) | -3.23 |
| Forward PE | -4.23 |
| Analyst | Buy |
| Ask | 2.94 |
| Volume | 1,417,468 |
| Avg. Volume (20D) | 1,321,558 |
| Open | 2.88 |
| Previous Close | 2.96 |
| Day's Range | 2.71 - 2.90 |
| 52-Week Range | 1.42 - 4.66 |
| Beta | 0.99 |
About ATYR
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connectiv...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 56
Stock Exchange NASDAQ
Ticker Symbol ATYR
Website https://www.atyrpharma.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ATYR stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 475.54% from the latest price.
Stock Forecasts1 month ago
+11.14%
ATyr Pharma shares are trading higher after Leerin...
Unlock content with
Pro Subscription
6 months ago
+7.47%
aTyr Pharma shares are trading higher after Wells Fargo initiated coverage on the stock with an Overweight rating and announced a price target of $17.
